Biodexa Pharmaceuticals (MTPH) Share Price, News & Analysis

Company Overview

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Key Stats

• Today's Range: 12.50 to 20
• 50-Day Range: 18 to 18
• 52-Week Range: 0.90 to 20
• Volume: 73,672 shs
• Average Volume: 617,252 shs
• Market Capitalization: £31.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MTPH Stock Analysis - Frequently Asked Questions

How have MTPH shares performed this year?

Biodexa Pharmaceuticals' stock was trading at GBX 18 at the beginning of the year. Since then, MTPH stock has increased by 0.0% and is now trading at GBX 18.
View the best growth stocks for 2024 here.

How were Biodexa Pharmaceuticals' earnings last quarter?

Biodexa Pharmaceuticals Plc (LON:MTPH) released its quarterly earnings results on Thursday, September, 10th. The company reported ($64.00) earnings per share (EPS) for the quarter.

How do I buy shares of Biodexa Pharmaceuticals?

Shares of MTPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Biodexa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include Aldeyra Therapeutics (ALDX), Barclays (BARC), Telefonaktiebolaget LM Ericsson (publ) (ERIC), Futura Medical (FUM), Lloyds Banking Group (LLOY), Biodexa Pharmaceuticals (MTP) and Intec Pharma (NTEC).

Company Calendar

• Last Earnings: 9/10/2020
• Today: 9/17/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Computer Software
• Current Symbol: LON:MTPH
• CUSIP: N/A
• CIK: N/A
• Web: www.midatechpharma.com
• Phone: +44-1235-841575
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,370,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -95.47%
• Return on Assets: -52.50%

Debt

• Debt-to-Equity Ratio: 9.52
• Current Ratio: 5.28
• Quick Ratio: 5.28

Sales & Book Value

• Annual Sales: £645,000.00
• Price / Sales: 48.38
• Cash Flow: GBX 20.53 per share
• Price / Cash Flow: 0.88
• Book Value: GBX 152 per share
• Price / Book: 0.12

Miscellaneous

• Outstanding Shares: 173,350,000
• Free Float: N/A
• Market Cap: £31.20 million
• Optionable: Not Optionable
• Beta: 1.22